Docetaxel: clinical benefit in first-line treatment for NSCLC

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1348, 2002-01, pp. : 15-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Irinotecan plus docetaxel a first-line option for NSCLC

By  

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Cisplatin + pemetrexed as first-line therapy for advanced NSCLC

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Cetuximab FLEXes muscle in first-line advanced NSCLC

By  

Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Docetaxel: A Review of its Use for the First-Line Treatment of Advanced Castration-Resistant Prostate Cancer

By McKeage Kate  

Drugs, Vol. 72, Iss. 11, 2012-07 ,pp. : 1559-1577

Adis International

Access to resources Recommend Favorite

Second-line pemetrexed, docetaxel similarly effective for NSCLC

By  

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite